

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*

Sheet

of

Complete if Known**Application Number** 09780035**Filing Date** 2001-02-09**First Named Inventor** Tariq Ghayur**Art Unit** 1644**Examiner Name** Gambel, Phillip**Attorney Docket Number** BBC-084/US**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	51	MCINNES, IAIN B. et al., Interleukin 18: a pleiotropic participant in chronic inflammation, Immunology Today (2000) Vol. 21, pgs. 312-315	
	52	MENDEZ, MICHAEL J. et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nature Genetics (1997), Vol. 15; 146-156	
	53	MIZUSHIMA, SEIICHI et al., pEF-BOS, a powerful mammalian expression vector, Nucleic Acids Research, (1990) Vol. 18(17), pg. 5322	
	54	MONTELEONE, GIOVANNI et al., Bioactive IL-18 Expression is up-Regulated in Chron's Disease, Journal of Immunology, (1999) Vol. 163(1), pgs. 143-147	
	55	NETEA, MIHAI G. et al., Neutralization of IL-18 Reduces Neutrophil Tissue Accumulation, The Journal of Immunology (2000) Vol. 164, pgs. 2644-2649	
	56	POLJAK, ROBERTO J., Production and Structure of diabodies, Structure (1994) , Vol. 2, pgs. 1121-1123	
	57	QUEEN, CARY et al., A human antibody that binds to the interleukin 2 receptor, Proc. Natl. Acad. Sci., (1989) Vol. 86, pgs. 10029-10033	
	58	REICHMANN, LUTZ et al., Reshaping human antibodies for therapy, Nature (1988), Vol. 332, pgs. 323-327	
	59	TAKEDA, KIYOSHI et al., Defective Nk Cell Activity and Th1 Response in IL-18 Deficient Mice, Immunity (1998) Vol. 8, pgs. 383-390	
	60	TANIGUCHI, MUTSUKO et al., Characterization of anti-human interleukin-18 (IL-18), Journal of Immun. Methods (1997) Vol. 206; 107-113	

Examiner Signature	/Phillip Gambel/	Date Considered	12/21/2009
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:**
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.